Access differs by indication, formulation, prescriber, funding rule, and current product supply. Each country page states what the cited public evidence can—and cannot—confirm.
About this site
Get Naltrexone
An independent educational resource checking naltrexone evidence, safety, product status, funding, and access across eight country health systems.
Our purpose
Get Naltrexone exists to make naltrexone evidence and access easier to verify. We cover approved uses, safety, the Sinclair Method, low-dose naltrexone, combination products, and country-specific treatment pathways.
Product status is not interchangeable across countries. A regulator may list a naltrexone-containing combination product without listing a currently marketed standalone 50 mg tablet. We therefore separate clinical evidence, regulatory status, funding, commercial availability, and patient cost instead of treating them as one claim.
What we provide
This site is built around four principles.
Evidence you can inspect
Clinical claims are tied to systematic reviews, trials, medicine labels, treatment guidelines, and official regulator or payer records. Primary sources are preferred where available.
No commercial interests
We do not sell naltrexone, accept pharmaceutical advertising, promote specific clinics, or include affiliate links. This site is an independent educational resource.
Patient-centred design
Pages lead with a direct answer and practical takeaways, then distinguish established evidence from uncertainty and local policy that can change.
Countries we cover
Eight country pages, with product-level confidence rather than assumptions from regional practice.
Australia and New Zealand
Official regulator and public-funding records support comparatively strong access guidance for standalone oral naltrexone.
United Kingdom, United States, and Canada
National labels and guidance establish clinical use, while coverage and supply details still depend on the product and local payer.
Singapore and the UAE
Current public records support Contrave evidence; this site does not infer a marketed standalone 50 mg product where one could not be verified.
South Africa
The official medicine price database currently records both Naltima 50 mg and Contrave, allowing product-specific rather than regional claims.
Compare the evidence
See what official sources confirm—and where availability or cost still needs local verification—across all eight countries.